Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Leap Therapeutics ( (LPTX) ) just unveiled an update.
On November 12, 2025, Cypherpunk Technologies Inc., formerly known as Leap Therapeutics, Inc., entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. This agreement allows the company to offer and sell shares of its common stock, with a total offering price of up to $200 million, through Cantor, acting as principal and/or sales agent. The sales will be conducted under the company’s shelf registration statement and can be terminated by either party with ten business days’ notice.
The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.
Spark’s Take on LPTX Stock
According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.
Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.
To see Spark’s full report on LPTX stock, click here.
More about Leap Therapeutics
Average Trading Volume: 3,541,541
Technical Sentiment Signal: Sell
Current Market Cap: $26.03M
For detailed information about LPTX stock, go to TipRanks’ Stock Analysis page.